Protocols

Scott Gottlieb clears another hurdle in last stretch ahead of the FDA; Sanofi inks €250M bispecific discovery deal in metabolics

Andrew Hopkins

→ The Senate voted to end debate on Scott Gottlieb’s nomination to run the FDA, setting up a final vote that is widely expected to confirm him in the position.

→ Scotland’s Exscientia forged a strategic research deal with Sanofi covering metabolic disease. Exscientia will go to work looking for new bispecifics, and Sanofi will provide research funding and up to €250 million in milestones. Andrew Hopkins, CEO, Exscientia said: “We are delighted that Sanofi is engaging with Exscientia in a comprehensive, end-to-end drug discovery project. This agreement highlights Exscientia’s ability to apply bispecific drug design in a comprehensive and highly productive manner.”

→ Scotland’s Elasmogen and Canada’s Feldan Therapeutics have agreed to collaborate with Amgen, using their technologies to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.

→ Sofinnova Ventures, Novo Seeds and Lundbeckfonden Emerge backed a €16.2 million round for Dermtreat ApS, which is developing a patch delivery tech.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->